Small Molecule Inhibitors for Treatment of Obesity and Metabolic Syndrome

SHIP1/2 inhibition for control of diet-induced obesity and improvement of blood glucose regulation. Background: Low-grade chronic inflammation has been established as the key etiological phenomenon responsible for the initiation and perpetuation of obesity and its associated metabolic disorders. Novel therapeutic approaches that can specifically target inflammatory mechanisms represent a promising pathway to address these health challenges. Technology Overview: Genetic and chemical inhibition of SH2-containing inositol 5-phosphatase 1 (SHIP1) has been associated with systemic expansion of immunoregulatory cells that promote a lean-body state. In addition, inactivation of its paralog SHIP2 in mice resulted in resistance to obesity following consumption of a high-fat diet. Novel small molecule compounds targeting SHIP1/2 have been shown to control diet-induced obesity and improve blood glucose regulation in an in vivo mouse model. Advantages: Novel approach to treating obesity, relative to the few existing solutions on the market, which focus on appetite suppression and/or are associated with major side effects. Applications: – Obesity

  • Diet-induced metabolic syndrome
  • Insulin resistance and glucose intolerance Intellectual Property Summary: – EP3016660 Ship inhibition to combat obesity
  • AU2014284360 Ship inhibition to combat obesity
  • CA2953917 Ship inhibition to combat obesity
  • US16/724,093 Ship inhibition to combat obesity Licensing Potential: Development partner, Commercial partner, Licensing, Seeking investment Licensing Status: This technology is available for licensing.


Contact Information

TTO Home Page:

Name: Tanya Waite

Title: Senior Partnership Mgr, Innovation & Partnerships

Department: Industry & External Affairs


Phone: (518) 434-7048